Can you give, without compromising any confidentiality obviously, but can you give me an example of somebody whose life went from under the previous, uh, protocols you had to these newer, faster, FAST protocols and treatments, somebody whose life has been restored to what it was, uh, prior to stroke?

Uh, yeah, so, um, so New Zealand's really good at stroke.

We are now treating, um, I think it's up to about twenty-five, uh, sorry, twenty percent of patients, you know, one in five patients with stroke with one of these treatments.

That's miraculous, and that's right up there in the world.

We're now treating about one in ten of our stroke patients with clot retrieval.

Um, and the important thing about that is the ones who get clot retrieval are the ones with the big clots, the ones we can get at.

These are the biggest, most disabling strokes.

So it's like a puddle seeping outwards.

But, but fundamentally, what, what contributes to that? And is this a-- is this a foregone era, or, or is this something we'll continue to experience with contemporary implants?

Historically, we started off with PGA, polyglycolic acid, for little pins and rods in the ankle fixation arena, and it morphed into other aspects.

And twenty-five percent of those had draining sinuses that were basically due to the rapidity with which that absorbs.

So that if you mix PGA, polyglycolic acid, with polylactile lactic acid and you get a copolymer, then that kind of slows things down.

Or you can go all the way to just pure PLLA, polylactile lactic acid, and that'll take you at least five years, uh, to grade and-- degrade.

And so it's, it's how you wanna mix your, your, uh, your material.

And the polymer scientists have tried to hit that sweet spot where it doesn't go away so fast that you get a lytic reaction that's symptomatic, but it does eventually go away.

Like, how would you respond? What are the concerns you have with that movement in that direction?